Exagen Q2 FY26 net loss narrows 28% to $3.2 million; revenue rises 16% to $19.9 million - XGN News | RalliesExagen Q2 FY26 net loss narrows 28% to $3.2 million; revenue rises 16% to $19.9 million
X
XGN• Volume and pricing trends
- Trailing-twelve-month average selling price rose 4% to $446 per test; AVISE CTD test volume climbed 11% year over year.
Full-year guidance and balance sheet
- Exagen raised full-year 2026 revenue guidance to $72 million-$75 million.
- The company ended the quarter with about $25 million in cash.
Q2 revenue and profitability improve
- Exagen posted Q2 revenue of $19.9 million, up 16% from Q2 2025, as it set record revenue and test volume.
- GAAP net loss narrowed to $3.2 million; GAAP operating loss tightened to $1.7 million.
- Non-GAAP adjusted EBITDA loss shrank to $114,000 from $1.7 million a year earlier.
